Alfacell Provides Update on ONCONASE Clinical Program

BLOOMFIELD, N.J., Jan. 19 /PRNewswire-FirstCall/ -- Alfacell Corporation(Nasdaq: ACEL) today announced that over 300 patients are now enrolled in theCompany's international, confirmatory Phase IIIb trial evaluating ONCONASE(R)(ranpirnase), the Company's lead investigational drug candidate, as atreatment for unresectable malignant mesothelioma (UMM). The required numberof patients for full enrollment is 316. The Company will continue to provideupdates as key developments occur. "We have been unwavering in our commitment to complete the ONCONASE UMMclinical program," stated Kuslima Shogen, Chief Executive Officer of Alfacell."In enrolling more than 300 patients, Alfacell is conducting one of thelargest global UMM studies ever undertaken. We now look forward to achievingmore milestones on our regulatory path towards bringing ONCONASE to market." About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on thediscovery, development and commercialization of novel therapeutics for cancer,using its proprietary RNase technology platform. ONCONASE(R) (ranpirnase),Alfacell's lead investigational drug candidate, is currently being evaluatedin several studies, including a Phase IIIb registration study for malignantmesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer(NSCLC). For more information, please visit http://www.alfacell.com. This press release includes statements that may constitute"forward- looking" statements, usually containing the words "believe,""estimate," "project," "expect" or similar expressions. Forward-lookingstatements involve risks and uncertainties that could cause actual results todiffer materially from the forward-looking statements. Factors that wouldcause or contribute to such differences include, but are not limited to,uncertainties involved in transitioning from concept to product, uncertaintiesinvolving the ability of the Company to finance research and developmentactivities, potential challenges to or violations of patents, uncertaintiesregarding the outcome of clinical trials, the Company's ability to securenecessary approvals from regulatory agencies, dependence upon third-partyvendors, and other risks discussed in the Company's periodic filings with theSecurities and Exchange Commission. By making these forward-lookingstatements, the Company undertakes no obligation to update these statementsfor revisions or changes after the date of this release.